McKinsey estimates $2T needed to rebuild US manufacturing capacity

Rebuilding America’s industrial base carries a price tag roughly equivalent to the entire GDP of Italy. The McKinsey Global Institute pegs the cost at $2 trillion in capital expenditures, about 6% of US GDP, to replace the most strategically exposed manufactured imports with domestic production.

The report, released May 21, maps out which corners of America’s $3 trillion annual import bill are genuinely dangerous to rely on. The answer: about $760 billion worth, or roughly a quarter of total manufactured imports, which McKinsey labels “Achilles’ heels” due to their concentration in geopolitically risky supply chains.

The scale of the problem

On average, domestic production of these vulnerable goods would need to double. That’s the baseline. Some sectors are far more extreme.

Active pharmaceutical ingredients, the chemical building blocks of the drugs Americans depend on, would require more than five times current US output. AI servers, the hardware backbone of the artificial intelligence boom, would need a tenfold increase in domestic manufacturing capacity.

US factories currently have enough spare capacity to generate only about $660 billion in additional output. That leaves a massive gap that requires entirely new facilities, trained workers, upgraded infrastructure, and additional energy sources.

Why this matters beyond trade policy

The Trump administration has pushed aggressively for bringing production home through a combination of tariffs and incentives, advocating for public-private investment models to close the gap.

The pharmaceutical sector illustrates the difficulty well. The US has spent decades offshoring API production to countries with lower labor and regulatory costs. Reversing that requires not just capital but specialized chemical engineering talent, regulatory approvals, and environmental permitting processes that take years, not quarters.

What this means for investors

Supply chain verification has emerged as one of blockchain’s most practical enterprise use cases. As companies and governments pour money into reshoring, the need to prove where goods actually come from, and whether domestic production claims hold up, becomes a compliance and national security priority.

Blockchain-based traceability solutions could see increased adoption in precisely the sectors McKinsey flags as most vulnerable: pharmaceuticals, electronics, and defense-adjacent manufacturing.

New factories need power. The AI server manufacturing McKinsey highlights is particularly energy-intensive, creating potential competition with Bitcoin mining operations and data centers for grid capacity.

Disclosure: This article was edited by Editorial Team. For more information on how we create and review content, see our Editorial Policy.